Company profile
Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06006702 | phase1 | active_not_recruiting | 2023-10-16 | 2025-05-01 | Tyra Biosciences, Inc | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants |
| NCT06842355 | phase2 | recruiting | 2025-03-04 | 2030-01-01 | Tyra Biosciences, Inc | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 |
| NCT06995677 | phase2 | recruiting | 2025-06-27 | 2028-02-01 | Tyra Biosciences, Inc | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer |
| NCT07265947 | phase2 | recruiting | 2025-12-22 | 2030-10-01 | Tyra Biosciences, Inc | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma |
| NCT06160752 | phase1 | active_not_recruiting | 2023-11-22 | 2026-09-01 | Tyra Biosciences, Inc | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations |
FDA applications (0)
No records yet.